LifeMD shares plummeted over 28% to $8.48 after the telemedicine company reported dismal Q2 2025 results, missing both revenue and earnings forecasts. The firm posted a loss of $0.06 per share—triple analysts’ expectations—while revenue of $62.2 million fell $4 million short. Compounding investor anxiety, management slashed its full-year revenue guidance to $250–255 million, down from $268–275 million. The RexMD men’s health division struggled with soaring customer acquisition costs and declining conversion rates, overshadowing growth in weight management, where 400+ daily sign-ups were marred by rising refund demands due to unaffordable branded drug costs.
Insider Moves and Structural Challenges
Despite CEO stock sales worth $250,000, LifeMD maintains ambitious 2025 targets, including $200 million from telemedicine and $55 million from WorkSimpli. While debt-free with $36.2 million cash, operational hurdles—particularly RexMD’s underperformance and pricing pressure from cheaper competitors—have eroded confidence. Analysts question whether the company can reconcile its optimistic projections with persistent execution risks.
